L. Leffet

发表

Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries.

G. Trainor, F. Hobbs, B. Stone, 1996, Nucleic acids research.

INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology

M. Bower, R. Wynn, Q. Wang, 2017, ACS medicinal chemistry letters.

Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase δ Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy

H. Koblish, M. Stubbs, Q. Wang, 2020, The Journal of Pharmacology and Experimental Therapeutics.

Selective inhibition of indoleamine 2 , 3-dioxygenase ( IDO 1 ) effectively regulates mediators of antitumor immunity

R. Wynn, Q. Wang, J. Fridman, 2010 .

Parsaclisib Is a Next-Generation PI3Kδ Inhibitor With Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy a

Kathy, Qianqian Wang, H. Koblish, 2020 .

INCB38579, a novel and potent histamine H₄ receptor small molecule antagonist with anti-inflammatory pain and anti-pruritic functions.

P. Scherle, L. Leffet, Yanlong Li, 2012, European journal of pharmacology.

Discovery and Pharmacological Characterization of a Novel Rodent-Active CCR2 Antagonist, INCB3344

P. Scherle, F. Baribaud, L. Leffet, 2005, The Journal of Immunology.

Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model.

Qian Wang, Michael Bower, Richard Wynn, 2009, Journal of medicinal chemistry.

Pharmacological characterization of INCB3344, a small molecule antagonist of human CCR2.

R. Wynn, P. Scherle, F. Baribaud, 2009, Biochemical and biophysical research communications.

Discovery and Pharmacological Characterization of a Novel Rodent-Active CCR2 Antagonist, INCB3344

P. Scherle, F. Baribaud, T. Burn, 2005, The Journal of Immunology.

Analysis of site-specific phosphorylation of the retinoblastoma protein during cell cycle progression.

L. Leffet, D. Sharp, J. Boylan, 1999, Experimental cell research.

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.

Qian Wang, Beth Thomas, Richard Wynn, 2010, Blood.

INCB040093 Is a Novel PI3Kδ Inhibitor for the Treatment of B Cell Lymphoid Malignancies

Jun Yu Li, Qianqian Wang, B. Rumberger, 2018, The Journal of Pharmacology and Experimental Therapeutics.

Discovery of Potent and Selective Inhibitors of Wild-Type and Gatekeeper Mutant Fibroblast Growth Factor Receptor (FGFR) 2/3.

H. Koblish, M. Deller, R. Klabe, 2022, Journal of medicinal chemistry.

Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.

R. Wynn, H. Koblish, Yue Zhang, 2021, Journal of medicinal chemistry.

Abstract 4712: Discovery of INCB059872, a novel FAD-directed LSD1 inhibitor that is effective in preclinical models of human and murine AML

R. Wynn, A. Margulis, X. Liu, 2016 .

Discovery of Orally Bioavailable FGFR2/FGFR3 Dual Inhibitors via Structure-Guided Scaffold Repurposing Approach.

April Horsey, L. Leffet, M. Covington, 2023, ACS Medicinal Chemistry Letters.

Discovery of Potent and Selective Inhibitors of Wild-Type and Gatekeeper Mutant Fibroblast Growth Factor Receptor (FGFR) 2/3

H. Koblish, M. Deller, R. Klabe, 2022, Journal of Medicinal Chemistry.

Characterization of a Novel Rodent-Active Discovery and Pharmacological

P. Scherle, F. Baribaud, L. Leffet, 2013 .

INCB040093 Is a Novel PI3Kδ Inhibitor for the Treatment of B Cell Lymphoid Malignancies

Jun Yu Li, Qianqian Wang, B. Rumberger, 2018, The Journal of Pharmacology and Experimental Therapeutics.